Medtronic plc stock gains as fiscal 2027 guidance is raised after strong first quarter
Published on 09/04/2026 at 15:27 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Medtronic plc (ISIN IE00BTN1Y115) stock is benefiting from strong fiscal 2027 first quarter figures, with adjusted earnings per share of 1.45 dollars and a raised full-year guidance reported in early September 2026, as investors digest both the earnings beat and updated outlook.
Strong first quarter sets the tone
According to a detailed earnings summary published on September 4, 2026, Medtronic reported adjusted earnings per share of 1.45 dollars for its fiscal 2027 first quarter, exceeding the analyst consensus estimate of 1.39 dollars by 0.06 dollars, or about 4.3 percent.
The same overview notes that fiscal 2027 first quarter revenue reached approximately 9.76 billion dollars, compared with a consensus expectation of 9.55 billion dollars, implying a beat of about 210 million dollars and year-over-year growth of 13.7 percent for the quarter ended July 31, 2026.
Guidance raised and organic growth outlook
In its fiscal 2027 guidance update for the year ending April 2027, Medtronic raised the target range for adjusted diluted earnings per share from 5.90 to 6.00 dollars to a slightly higher band of 5.94 to 6.00 dollars, tightening the range while nudging the lower end up by 0.04 dollars based on the first quarter performance.
The same guidance revision also increased the expected organic revenue growth range for fiscal 2027 from 6.75 to 7.25 percent to a new band of 7.25 to 7.75 percent, adding 0.5 percentage points to the midpoint and signaling confidence that double-digit reported growth in the first quarter can translate into high single digit organic growth for the full year.
More on Medtronic plc and its latest figures
Investors can find additional details on Medtronic plc, including historical news and data, through the company overview and stock-specific topics page.
Analyst consensus and valuation context
Analyst data compiled by a stock analysis portal on September 4, 2026 show that Medtronic currently carries a consensus rating described as moderate buy, based on 19 buy ratings and 9 hold ratings, with an average price target of about 102.36 dollars per share.
With the same portal indicating that Medtronic stock was trading around 91.92 dollars recently and that shares started the year at approximately 96.13 dollars, the implied upside to the average price target is about 11.4 percent, while the year to date performance reflects a decline of roughly 4.4 percent from the beginning of 2026.
Recent price performance and same-day moves
Market data from a European stock portal show that Medtronic shares closed at 93.10 dollars on the New York Stock Exchange on September 3, 2026, marking a daily gain of 1.00 percent.
The same overview highlights that Medtronic stock was up about 3.48 percent over the preceding five trading days as of the end of trading on September 3, 2026, while the year to date performance stood at a decline of 3.08 percent, underscoring that the recent rebound has not yet fully offset earlier weakness.
Endurant stent graft receives updated CE labeling
On September 3, 2026 Medtronic announced that the Endurant stent graft system, used for the treatment of abdominal aortic aneurysms, received updated Conformite Europeenne labeling removing a prior rupture treatment warning, according to an official company announcement.
This change makes Endurant the first and, as of the announcement date, only stent graft system with this particular CE mark update for rupture labeling, which may support Medtronic's vascular segment growth in Europe by widening the approved use of an established device platform.
Product focus: Endurant stent graft system
Endurant is Medtronic's flagship stent graft system designed for endovascular aortic repair, particularly in patients with abdominal aortic aneurysms who are suitable for minimally invasive treatment.
With the updated European labeling announced on September 3, 2026, the product gains additional clinical flexibility in treating rupture cases under CE approval, which can be relevant for hospital purchasing decisions and could contribute to sustaining the double digit revenue growth reported in the fiscal 2027 first quarter as aneurysm treatment demand continues.
Stock level and investor perspective
Based on intraday trading indications around midday on September 4, 2026, Medtronic shares were quoted near 93.77 dollars on the New York Stock Exchange, approximately 2 percent above the prior closing level of 92.18 dollars reported for September 2, 2026, and slightly above the 93.10 dollar closing price noted for September 3, 2026, keeping the stock within a narrow band while investors weigh the raised guidance and regulatory developments.
Medtronic plc stock at a glance
- Company: Medtronic plc
- ISIN: IE00BTN1Y115
- Ticker: MDT
- Trading venue: NYSE
- Price (as of September 4, 2026): 93.77 USD
- Market capitalization: 117,280,000,000 USD (as of September 3, 2026)
- Sector / Industry: Health Care Equipment
- Index membership: S&P 500
